Humanoid Global: A Real Robotic Catalyst, Tiny Stakes, and a Premium Awaiting Proof

Humanoid Global Holdings (CSE:ROBO, OTCQB:RBOHF) changed chief executives for the third time in about fifteen months this week, and the stock closed the announcement day up roughly seven percent to about C$0.32 — a market value near C$14 million. The returning CEO, board member Sunny Ray, is an engineer and entrepreneur whose background sits in robotics and embodied AI, and who previously ran the company — so a superficial read is easy: continuity, momentum, buy the story. The real question is whether the change alters anything that actually decides the stock.

To answer that, it helps to be precise about what this company is. Humanoid Global is a Canadian "investment issuer" — a public company whose product is its portfolio, effectively a venture fund with a stock ticker. Formerly New Wave Holdings, a struggling esports and Web3 investor, it renamed itself in June 2025 and rebranded around one theme: private companies that make and deploy humanoid robots and embodied AI. Its disclosed portfolio includes a stake in Agility Robotics, maker of the Digit warehouse robot; an unnamed U.S. humanoid developer that has raised over US$1 billion; Formic, a robots-as-a-service provider; the HowToRobot marketplace; Cartwheel Robotics; RideScan; and MBody AI. These are real, high-profile names — the sector's version of owning pre-IPO exposure without the venture-fund lockups.

The catalyst that has been carrying the stock is legitimate. Agility Robotics struck a deal in June to go public through a merger with Churchill Capital Corp XI, a SPAC, at a US$2.5 billion pre-money valuation, with more than US$620 million in expected gross proceeds. Agility says it holds over US$300 million in multi-year orders for its Digit v5 robot and has logged more than 65,000 operating hours across nine customer facilities. For a holder of Agility shares, a completed listing would convert a private mark into a public one.

Here is where the thesis runs into arithmetic. Humanoid Global's disclosed cost basis in Agility is not US$25 million or even US$5 million — the company committed roughly US$145,000 in September 2025, through a fund that holds Agility shares, and closed it via a single-asset special purpose vehicle. Its Formic commitment was about US$100,000. Even a tenfold return on the Agility position — an optimistic assumption — produces roughly US$1.5 million, less than a sixth of this company's market value. Humanoid Global describes itself as a minority interest that is not a party to the SPAC deal and has no control over its completion or timing. Nothing in the balance sheet yet shows the portfolio being worth the price.

That balance sheet is the gap the stock trades on. Humanoid Global sits at about C$3 million in cash against a market capitalization near C$14 million — roughly five times its cash, and about 5.7 times book value per a recent quote service. It has no revenue; it is an investment issuer. Its trailing-twelve-month net loss is around C$6 million, more than its entire cash balance, and the share count rose almost 15% in the most recent quarter. In the fiscal year ended March 2026 it raised C$3.5 million across three private placements. The model requires continuous new capital, and each raise dilutes the existing holders who are paying the premium.

This is the tension a shareholder is really buying: a stock priced to assume meaningful portfolio mark-ups, in a company that has not published a stated net asset value and whose disclosed ticket sizes are five-figure. The premium over cash is, in effect, the market's down payment on listings that have not happened yet — Agility's SPAC, and the proposed merger of portfolio company MBody AI into Nasdaq-listed Check-Cap, where MBody's owners are expected to wind up with about 90% of the combined company and a close targeted for the third quarter.

Which brings us back to the CEO handoff. Shahab Samimi, the venture-background chief brought in last August to run the investment program, resigned effective August 21. In exchange for stepping down he received accelerated vesting of stock options and restricted share units, pro-rata vesting on additional awards, consulting fees through his resignation date, and — the detail worth pausing on — a contingent finder's fee on a transaction opportunity he introduced. The company did not name the transaction. That contractual toll bridge is a reminder that inside this public company beats a fee-generating deal shop, and it signals that a strategic deal is likely still in motion: as far back as February, management said the primary 2026 focus was a strategic acquisition or joint venture to establish a core operating business, including China and defence-and-security exposure. Sunny Ray, meanwhile, is a board member and former chief executive who founded the robotics venture Rosey.ai and has been granted 200,000 immediately-vesting options at $0.32, near the current price.

For a reader deciding whether to own this, separate the asset from the ticket. The underlying theme — humanoid robots moving from demonstrations into paid commercial deployments — is genuinely investable, and Agility's pending listing is a real event, not a rumor. But the way to own that event is not necessarily through a C$14 million cash-dominated shell whose stake in the biggest name is a US$145,000 commitment, whose reported economics are a C$6 million annual loss against C$3 million of cash, and whose share base keeps growing as it funds new positions. The stock is down roughly 47% over the past year and trades in 30,000-share days, so the multiple has reset — but it has reset from an even more expensive level, not to cheap.

The verdict is not a buy, and it is not quite a sell on the evidence either: it is too early. The premium demands proof only management can supply, and the calendar provides three windows to look for it. First, when the Agility SPAC closes — targeted this year — does Humanoid Global finally disclose the size, cost, and carrying value of its stake, rather than repeating that it holds a minority interest? Second, does the Check-Cap merger close in the third quarter, and does MBody's public value show up in Humanoid Global's marks? Third, in the coming financial statements, does the fair value of the investment portfolio rise to meet the market capitalization, and does the cash-and-dilution treadmill slow? Until then, the stock's price is a bet on a mark-up that the company has declined to show its work on. The CEO change, whoever occupies the chair, does nothing to change that.